Orthocell MD, Paul Anderson, presented at the Canaccord Genuity South-West Connect ASX Showcase today to share the latest news and developments for the Company’s Ortho-ATI™ and CelGro™ platform technologies.
Orthocell (ASX:OCC) announces positive data on CelGro collagen rope for ACL repair
Orthocell has been featured in The Market Herald, following our announcement of positive data from a pre-clinical study for anterior cruciate ligament (ACL) reconstruction.
Orthocell (ASX:OCC) granted patents in Canada and Hong Kong for CelGro
Orthocell has been featured in The Market Herald, following our announcement of patents granted in Canada and Hong Kong for CelGro.
Video | Proactive Investors – September 2021
Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about passing a key milestone in the OrthoATI™ rotator cuff tendon study.
Orthocell’s (ASX:OCC) final patient completes treatment in tendon regeneration study
Orthocell has been featured in The Market Herald, highlighting the follow-up announcement from our OrthoATI™ rotator cuff tendon regeneration study.
Video | Proactive Investors – Orthocell highlights potential for CelGro in treatment of lymphedema
Orthocell CEO and Managing Director Paul Anderson speaks to Proactive after announcing a breakthrough tissue engineering study, combining CelGro™ with lymphatic and blood vessel cells to create functional lymphatic tissue, has been published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Orthocell (ASX:OCC) has breakthrough tissue engineering study published in US
Orthocell has been featured in The Market Herald, following the publication of our breakthrough tissue engineering study in the peer-reviewed journal “Proceedings of the National Academy of Sciences of the United States of America”.
Orthocell (ASX:OCC) appoints exclusive distributor for Striate+
Orthocell has been featured in The Market Herald, announcing the appointment of Samson Medical Technologies (SMT) as its exclusive distributor for Striate+ across Australia.
Video | Stockhead Investor Presentation – June 2021
Orthocell CEO and Managing Director Paul Anderson spoke with Oriel Morrison as part of Stockhead V-Con Biotechs.
Video | Ticker News Interview – June 2021
Orthocell CEO and Managing Director, Paul Anderson, spoke with Ticker News about the positive findings from our CelGro™ clinical study.